Morgan Stanley lifts Gilead Sciences target to $175, keeps Overweight rating

Morgan Stanley analyst Terence Flynn lifted Gilead Sciences' price target to $175 and maintained an Overweight rating, according to a note dated April 10【1】.

The adjustment matters because Gilead is set to release its first‑quarter earnings next week, and investors watch analyst targets for clues on valuation and market sentiment【2】. A higher target can buoy the stock, while divergent analyst opinions highlight uncertainty in the biotech sector.

Flynn said the new target reflects updated biopharma models that improve forecasts for Gilead's pipeline and cash flow, moving the target up from $171【1】. The Overweight rating suggests the firm expects the stock to outperform the broader market, a step above a neutral stance.

However, a separate Globe and Mail release reported that Morgan Stanley reaffirmed a buy rating with a lower price target of $151【3】. The discrepancy underscores that analysts may use different assumptions or time horizons when forming outlooks, and both figures now appear in public filings.

Gilead's shares closed at $140.45 on the most recent trading day, up 1.02%【4】, while the S&P 500 posted a 1.18% gain【4】. The stock’s modest rise trails the broader index, indicating that the market has yet to fully price in the higher target.

Flynn said the firm’s confidence stems from recent advances in Gilead's antiviral and oncology programs, which could drive revenue growth in the coming quarters—factors that may justify the higher $175 projection if the products meet market expectations【2】.

**What this means** Investors should weigh the two conflicting targets and consider the analyst’s rationale for the upward revision. The higher $175 target implies upside potential if Gilead’s pipeline delivers, but the $151 figure reflects a more cautious outlook. Monitoring the upcoming earnings report will be key to gauging which scenario is more likely to materialize.